ImmunityBio Investor Relations Material

ImmunityBio Inc is a clinical-stage biotechnology company. We develop therapies and vaccines to treat cancers and infectious diseases. Our immunotherapy platform includes antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies and natural killer cells. We are currently completing several Phase II clinical trials for the treatment of solid and liquid tumors including bladder, pancreatic and lung cancers, as well as pathogens such as SARS-CoV-2 and HIV.